HexaBody-CD27 clinical trials

First-in-Human, Open-label, Dose-Escalation Trial with Expansion Cohorts to Evaluate the Safety of GEN1053 as Monotherapy and in Combination With an Immunomodulator in Subjects with Malignant Solid Tumors

This study is testing a new medicine called HexaBody-CD27 for people with solid tumours that have spread. It's looking at how safe the medicine is, how much to give, and if it can help shrink tumours. It's an early-stage study to understand this new treatment better.